Onychomycosis (Tinea Unguium) – Drugs in Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis – Drugs in Development, 2021, provides an overview of the Onychomycosis (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis – Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Onychomycosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 7, 1, 4, 1 and 2 respectively.

Onychomycosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Onychomycosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Onychomycosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Onychomycosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Acea Biotech Inc

Almirall SA

ASCIL Biopharm

Blueberry Therapeutics Ltd

CSA Biotechnologies LLC

DermBiont Inc

Exodos Life Sciences Limited Partnership

Hallux Inc

Hexima Ltd

Kaken Pharmaceutical Co Ltd

Moberg Pharma AB

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Onychomycosis (Tinea Unguium) - Overview

Onychomycosis (Tinea Unguium) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Onychomycosis (Tinea Unguium) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development

Acea Biotech Inc

Almirall SA

ASCIL Biopharm

Blueberry Therapeutics Ltd

CSA Biotechnologies LLC

DermBiont Inc

Exodos Life Sciences Limited Partnership

Hallux Inc

Hexima Ltd

Kaken Pharmaceutical Co Ltd

Moberg Pharma AB

Mycovia Pharmaceuticals Inc

NAL Pharmaceuticals Ltd

Novabiotics Ltd

Photonamic GmbH & Co KG

SaNOtize Research and Development Corp

Onychomycosis (Tinea Unguium) - Drug Profiles

aminolevulinic acid hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amphotericin B sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BB-0305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DBI-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELS-160 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HXP-124 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-607 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAL-3210 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NORS-0791 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-213 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onymed - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

oteseconazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-3058 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Disrupt Cell Membrane for Onychomycosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbinafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbinafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

terbinafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Onychomycosis (Tinea Unguium) - Dormant Projects

Onychomycosis (Tinea Unguium) - Discontinued Products

Onychomycosis (Tinea Unguium) - Product Development Milestones

Featured News & Press Releases

Jan 07, 2021: Updated timeline to phase IIb results

Oct 14, 2020: Moberg Pharma intends to submit a registration application in Europe in 2021

Jun 25, 2020: Moberg Pharma meets primary endpoint in the European phase 3 study

Mar 23, 2020: All patients in the European MOB-015 Phase 3 study have completed their last visit

Jan 28, 2020: Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603

Jan 22, 2020: Expert evaluation clarifies phase 3 results and provides strong support for MOB-015

Dec 12, 2019: Moberg Pharma comments on the results of the North American Phase 3 study with MOB-015

Dec 09, 2019: Moberg Pharma meets primary endpoint for MOB-015 in a phase 3 study for the treatment of Onychomycosis

Apr 18, 2019: UK-Based Nanomedicine firm set plans to initiate a large phase II efficacy study in 2019

Mar 22, 2019: Moberg Pharma completes enrollment for MOB-015 phase 3 study in Europe

Dec 18, 2018: Almirall announces that the Phase III trial of P-3058 for onychomycosis achieved primary endpoint

Nov 23, 2018: Blueberry reports positive results from Phase I/II BB2603 trial

Nov 23, 2018: Moberg Pharma: Patent granted for MOB-015 in China

Sep 11, 2018: Moberg Pharma has completed enrollment to Phase 3 study for MOB-015 in North America

Nov 21, 2017: Hexima Receives Approval to Conduct a Phase 1/2a Study for Fungal Nail Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Onychomycosis (Tinea Unguium), 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Acea Biotech Inc, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Almirall SA, 2021

Onychomycosis (Tinea Unguium) – Pipeline by ASCIL Biopharm, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Blueberry Therapeutics Ltd, 2021

Onychomycosis (Tinea Unguium) – Pipeline by CSA Biotechnologies LLC, 2021

Onychomycosis (Tinea Unguium) – Pipeline by DermBiont Inc, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Exodos Life Sciences Limited Partnership, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Hallux Inc, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Hexima Ltd, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Kaken Pharmaceutical Co Ltd, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Moberg Pharma AB, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Mycovia Pharmaceuticals Inc, 2021

Onychomycosis (Tinea Unguium) – Pipeline by NAL Pharmaceuticals Ltd, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Novabiotics Ltd, 2021

Onychomycosis (Tinea Unguium) – Pipeline by Photonamic GmbH & Co KG, 2021

Onychomycosis (Tinea Unguium) – Pipeline by SaNOtize Research and Development Corp, 2021

Onychomycosis (Tinea Unguium) – Dormant Projects, 2021

Onychomycosis (Tinea Unguium) – Dormant Projects, 2021 (Contd..1)

Onychomycosis (Tinea Unguium) – Dormant Projects, 2021 (Contd..2)

Onychomycosis (Tinea Unguium) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Onychomycosis (Tinea Unguium), 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports